Table 1.
Patients' characteristics
| 90 years+ | 80–89 years | <80 years | P‐value | |
|---|---|---|---|---|
| n = 25 | n = 185 | n = 283 | ||
| Clinical characteristics | ||||
| Age (years) | 91.0 (90, 92) | 83.0 (81, 85) | 73.5 (67, 77) | 0.001* |
| Gender (F/M), n (%) | 15/10 (60/40) | 91/94 (49/51) | 99/184 (35/65) | 0.015* |
| Extracardial vascular disease, n (%) | 4 (16.0) | 46 (24.9) | 57 (20.1) | 0.298 |
| Diabetes mellitus, n (%) | 5 (20.0) | 57 (30.8) | 94 (33.2) | 0.377 |
| COPD, n (%) | 2 (8.0) | 35 (19.0) | 62 (21.9) | 0.221 |
| Prior stroke, n (%) | 1 (4.0) | 13 (7.0) | 18 (6.3) | 0.839 |
| Previous cardiac surgery, n (%) | 2 (8.8) | 32 (17.3) | 85 (30.0) | 0.001* |
| Atrial fibrillation, n (%) | 19 (76.0) | 128 (69.2) | 191 (67.5) | 0.662 |
| Logistic EuroSCORE | 20.0 (17.0, 31.5) | 23.0 (13.9, 35.0) | 19.0 (9.5, 30.1) | 0.070 |
| STS risk score (%) | 6.7 (3.7, 9.8) | 8.5 (5.6, 10.6) | 8.2 (7.5, 11.1) | 0.128 |
| Charlson Comorbidity Index | 5.5 (5.0, 6.0) | 6.0 (5.0, 8.0) | 5.0 (4.0, 7) | 0.001* |
| NYHA III/IV, n (%) | 25 (100) | 157 (84.9) | 247 (87.3) | 0.301 |
| Echocardiographic/haemodynamic data | ||||
| DMR/FMR, n (%) | 11/14 (44/56) | 72/113 (39/61) | 83/200 (29/71) | 0.053 |
| LVEDD (mm) | 54 (49, 59.5) | 55 (49, 61) | 58 (49, 65) | 0.258 |
| LA diameter (mm) | 40 (36, 44.5) | 41 (34, 46) | 39 (33, 45) | 0.110 |
| LVEF (%) | 45 (40, 50) | 42 (35, 50) | 40 (30, 49) | 0.020* |
| LVEF > 50%, n (%) | 11 (44) | 75 (40.5) | 79 (27.9) | 0.001* |
| LVEF 40–50%, n (%) | 10 (40) | 32 (17.3) | 54 (19.1) | |
| LVEF < 40%, n (%) | 4 (16) | 78 (42.2) | 150 (53.0) | |
| TAPSE (mm) | 17 (15, 20) | 17 (15, 21) | 17 (15, 20) | 0.850 |
| Moderate/severe TR, n (%) | 16 (64%) | 102 (55.1) | 144 (50.8) | 0.357 |
| Cardiac index (mL/min/m2) | 2.0 (1.8, 2.3) | 2.0 (1.7, 2.3) | 2.0 (1.7, 2.3) | 0.975 |
| PAPs (mmHg) | 46 (40, 56) | 53 (43, 66) | 51 (41, 62) | 0.120 |
| Laboratory assessment | ||||
| Haemoglobin (g/dL) | 12 (11.0, 12.9) | 11.7 (10.5, 12.8) | 12.2 (10.7, 13.6) | 0.290 |
| Estimated GFR (mL/min) | 38.0 (30, 50.0) | 44 (35, 60) | 52 (37, 67) | 0.002* |
| NT‐proBNP (pg/mL) | 3068 (1991, 6182) | 2521 (1399, 5010) | 2515 (1381, 4691) | 0.139 |
COPD, chronic obstructive pulmonary disease; DMR, degenerative mitral regurgitation; FMR, functional mitral regurgitation; GFR, glomerular filtration rate; LA, left atrial; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; NYHA, New York Heart Association; PAPs, pulmonary artery systolic pressure; STS, Society of Thoracic Surgeons scores for the risk of death within 30 days after mitral valve repair; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
Values are n (%) or median (inter‐quartile range).
*
P ≤ 0.05 among the groups.